| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -46.4 | -21.7 |
| EPS (diluted, $ a share) | $-3.19 | $-39.49 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: KRSA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Korsana Biosciences, Inc.: key numbers
- Share price
- $32.50Close, Nov 17
- Market cap
- $1.48B
- Shares outstanding
- 45.54MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Korsana Biosciences, Inc.
All →Korsana Biosciences Financial Results
Korsana Biosciences reported third quarter 2026 financial results, highlighting a cash position of $456.2 million following its merger with Cyclerion Therapeutics and a $380 million private placement. The company expects its current capital to fund operations into 2029 as it advances its lead Alzheimer's candidate, KRSA-028, toward Phase 1 clinical data in mid-2027.
- Term
- Q3 2026
“The third quarter was transformative for Korsana, providing us with the financial resources and experienced leadership team to execute our strategy. With this foundation in place, we remain focused on advancing KRSA-028 toward the clinic and building the body of evidence supporting the program, including through our first preclinical poster at CTAD later this month.”
Jonathan Violin, Ph.D., President and Chief Executive Officer